Pooja Singh

Pooja Singh

Auto-generated profile, based on publicly available information

Pooja Singh

Thomas Jefferson University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 July 2010 in Transplantation
Verified
Journal Article
Closed access
PSPooja Singh
Pooja Singh
BCBeth W. Colombe
Beth W. Colombe
GFGeorge C. Francos
George C. Francos
MCMaria P Martinez Cantarin
Maria P Martinez Cantarin
AFAdam M. Frank
Adam M. Frank

15 December 2015 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
PSPooja Singh
Pooja Singh
EFEdward J. Filippone
Edward J. Filippone
BCBeth W. Colombe
Beth W. Colombe
ASAshesh P. Shah
Ashesh P. Shah
TZTingting Zhan
Tingting Zhan
AFAdam M. Frank
Adam M. Frank

14 June 2017 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DAD. Axelrod
D. Axelrod
KLKrista L Lentine
Krista L Lentine
MSM. A. Schnitzler
M. A. Schnitzler
XLX. Luo
X. Luo
HXH. Xiao
H. Xiao
DSD. L. Segev
D. L. Segev
Incompatible living donor kidney transplantation (ILDKT) has been established as an effective option for end‐stage renal disease patients with willing but HLA‐incompatible living donors, reducing mortality and improving quality of life. Depending on antibody titer, ILDKT can require highly resource‐intensive procedures, including intravenous immunoglobulin, plasma exchange, and/or cell‐depleting antibody treatment, as well as protocol biopsies and donor‐specific antibody testing. This study sought to compare the cost and Medicare reimbursement, exclusive of organ acquisition payment, for ILDKT (n = 926) with varying antibody titers to matched compatible transplants (n = 2762) performed between 2002 and 2011. Data were assembled from a national cohort study of ILDKT and a unique data set linking hospital cost accounting data and Medicare claims. ILDKT was more expensive than matched compatible transplantation, ranging from 20% higher adjusted costs for positive on Luminex assay but negative flow cytometric crossmatch, 26% higher for positive flow cytometric crossmatch but negative cytotoxic crossmatch, and 39% higher for positive cytotoxic crossmatch (p < 0.0001 for all). ILDKT was associated with longer median length of stay (12.9 vs. 7.8 days), higher Medicare payments ($91 330 vs. $63 782 p < 0.0001), and greater outlier payments. In conclusion, ILDKT increases the cost of and payments for kidney transplantation.

22 February 2017 in Transplant Infectious Disease
Verified
Journal Article
Closed access
ASAshesh P. Shah
Ashesh P. Shah
ACAndrew Cameron
Andrew Cameron
PSPooja Singh
Pooja Singh
AFAdam M. Frank
Adam M. Frank
JFJonathan M. Fenkel
Jonathan M. Fenkel

27 February 2021 in American Journal of Transplantation
Verified
Journal Article
Open access
JMJennifer D. Motter
Jennifer D. Motter
KJKyle R. Jackson
Kyle R. Jackson
JLJane J. Long
Jane J. Long
MWMadeleine M. Waldram
Madeleine M. Waldram
BOBabak J. Orandi
Babak J. Orandi
JGJacqueline M. Garonzik-Wang
Jacqueline M. Garonzik-Wang
Incompatible living donor kidney transplant recipients (ILDKTr) have pre-existing donor-specific antibody (DSA) that, despite desensitization, may persist or reappear with resulting consequences, including delayed graft function (DGF) and acute rejection (AR). To quantify the risk of DGF and AR in ILDKT and downstream effects, we compared 1406 ILDKTr to 17 542 compatible LDKT recipients (CLDKTr) using a 25-center cohort with novel SRTR linkage. We characterized DSA strength as positive Luminex, negative flow crossmatch (PLNF); positive flow, negative cytotoxic crossmatch (PFNC); or positive cytotoxic crossmatch (PCC). DGF occurred in 3.1% of CLDKT, 3.5% of PLNF, 5.7% of PFNC, and 7.6% of PCC recipients, which translated to higher DGF for PCC recipients (aOR = 1.03 1.682.72 ). However, the impact of DGF on mortality and DCGF risk was no higher for ILDKT than CLDKT (p interaction > .1). AR developed in 8.4% of CLDKT, 18.2% of PLNF, 21.3% of PFNC, and 21.7% of PCC recipients, which translated to higher AR (aOR PLNF = 1.45 2.093.02 ; PFNC = 1.67 2.403.46 ; PCC = 1.48 2.243.37 ). Although the impact of AR on mortality was no higher for ILDKT than CLDKT (p interaction = .1), its impact on DCGF risk was less consequential for ILDKT (aHR = 1.34 1.621.95 ) than CLDKT (aHR = 1.96 2.292.67 ) (p interaction = .004). Providers should consider these risks during preoperative counseling, and strategies to mitigate them should be considered.

29 January 2012 in Clinical Transplantation
Verified
Journal Article
Closed access
PDF file
PSPooja Singh
Pooja Singh
JFJohn L. Farber
John L. Farber
CDCataldo Doria
Cataldo Doria
GFGeorge C. Francos
George C. Francos
RGRakesh Gulati
Rakesh Gulati
AFAdam M. Frank
Adam M. Frank